Phase 3 Recruiting NIH
This phase III trial compares the addition of induction chemotherapy, with carboplatin, paclitaxel and pembrolizumab, to chemotherapy and radiation, with cisplatin and pembrolizumab followed by pembrolizumab maintenance for the treatment o…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07061977
Sites in Louisiana: - West Jefferson Medical Center — Marrero, Louisiana
- East Jefferson General Hospital — Metairie, Louisiana
- LSU Healthcare Network / Metairie Multi-Specialty Clinic — Metairie, Louisiana
- University Medical Center New Orleans — New Orleans, Louisiana
- Ochsner Baptist Medical Center — New Orleans, Louisiana
Phase 3 Recruiting Industry
Researchers are looking for new ways to treat metastatic cervical cancer. Cervical cancer is cancer in the cervix, the lower part of the uterus (womb). Metastatic means the cancer has spread to other parts of the body. Researchers want to …
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT07216703
Sites in Louisiana: - TRIALS 365 ( Site 6008) — Shreveport, Louisiana
Phase 3 Recruiting Industry
This is a phase III, randomized, double-blind, placebo-controlled, multi-center, global study to explore the efficacy and safety of volrustomig in women with high-risk LACC (FIGO 2018 stage IIIA to IVA cervical cancer) who have not progres…
Sponsor: AstraZeneca
NCT ID: NCT06079671
Sites in Louisiana: - Research Site — New Orleans, Louisiana
- Research Site — New Orleans, Louisiana
- Research Site — Shreveport, Louisiana
Phase 3 Recruiting Industry
The purpose of this study is to compare the efficacy and safety of ficlatuzumab plus cetuximab compared to placebo plus cetuximab in participants with recurrent/metastatic (R/M) HPV-negative Head and Neck Cancer. The primary hypothesis is …
Sponsor: AVEO Pharmaceuticals, Inc.
NCT ID: NCT06064877
Sites in Louisiana: - Mary Bird Perkins Cancer Center — Baton Rouge, Louisiana
Phase 2 Recruiting NIH
This phase II trial tests the addition of chemotherapy, with carboplatin and paclitaxel, or chemo-immunotherapy, with carboplatin, paclitaxel and cemiplimab to standard salvage surgery followed by post operative radiation therapy and cispl…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07195734
Sites in Louisiana: - LSU Health Baton Rouge-North Clinic — Baton Rouge, Louisiana
- Our Lady of the Lake Physician Group — Baton Rouge, Louisiana
- Our Lady of The Lake — Baton Rouge, Louisiana
Phase 2 Recruiting NIH
This phase II trial tests effects of nivolumab in combination with chemotherapy drugs prior to radiation therapy patients with nasopharyngeal carcinoma (NPC). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06064097
Sites in Louisiana: - Children's Hospital New Orleans — New Orleans, Louisiana
Phase 1, Phase 2 Recruiting Industry
Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with adv…
Sponsor: Turning Point Therapeutics, Inc.
NCT ID: NCT03093116
Sites in Louisiana: - Local Institution - 2116 — New Orleans, Louisiana
Phase 2 Recruiting NIH
This phase II trial compares the effectiveness of cemiplimab with CDX-1140 to cemiplimab without CDX-1140 prior to surgery in treating patients with stage III-IV head and neck cancer. Immunotherapy with monoclonal antibodies, such as cemip…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06980038
Sites in Louisiana: - Ochsner Medical Center Jefferson — New Orleans, Louisiana
Phase 2 Recruiting Academic/Other
The purpose of this research is to test the effectiveness and safety of the study drugs (VS-6766 and defactinib), and see what effects (good and bad) these drugs have on the patients with endometrioid cancer, mucinous ovarian cancer, high-…
Sponsor: University of Oklahoma
NCT ID: NCT05512208
Sites in Louisiana: - Louisiana State University Medical Center New Orleans — New Orleans, Louisiana
Recruiting Industry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…
Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Louisiana: - Massive Bio SYNERGY-AI site — New Orleans, Louisiana
Recruiting Industry
The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-stage solid tumors. It is necessary that ctDNA test results are linked to clinica…
Sponsor: Guardant Health, Inc.
NCT ID: NCT05059444
Sites in Louisiana: - Tulane Cancer Center — New Orleans, Louisiana
- Christus Highland/ Boniol — Shreveport, Louisiana
NA Recruiting NIH
This clinical trial evaluates the use of self-collected vaginal samples for human papillomavirus (HPV) testing in patients referred for a colposcopy and/or cervical excisional procedures to improve cervical cancer prevention. HPV is a comm…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07281430
Sites in Louisiana: - Louisiana State University — Lafayette, Louisiana
- Louisiana State University Health Science Center — New Orleans, Louisiana
Phase 4 Recruiting Academic/Other
The primary objective of this study is to determine the magnitude and breadth of the serum antibody response to the nonavalent HPV vaccine (Gardasil-9) in adults with well-controlled HIV infection. The secondary objectives of the study are…
Sponsor: Louisiana State University Health Sciences Center in New Orleans
NCT ID: NCT05266898
Sites in Louisiana: - University Medical Center New Orleans — New Orleans, Louisiana